Class Action Lawsuit Filed Against 3D Systems Corporation over Securities Law Violations

Strategic Insights -

3D Systems Corporation, a leading provider of 3D printing and digital manufacturing solutions, has been hit with a class action lawsuit for allegedly violating federal securities laws. The lawsuit, filed by Pomerantz LLP, claims that the Company's top officials made false and misleading statements regarding its business, operations, and compliance policies during the Class Period. The complaint alleges that 3D Systems had understated the impact of weakened customer spending on its business and overstated its resilience in challenging industry conditions.

The lawsuit centers around the Company's partnership with United Therapeutics Corporation, a biotechnology company, to develop 3D-printed lungs for patients with end-stage lung disease. The partnership's milestone criteria were updated in 2024, which negatively impacted the Company's Regenerative Medicine Program revenue. The complaint also claims that 3D Systems had overstated its resilience in the face of weakened customer spending and macroeconomic uncertainty.

The lawsuit comes after 3D Systems' financial results for the fourth quarter and full-year 2024 were disappointing, with the Company reporting a -3.4% year-over-year decline in sales revenue and a $9 million revenue reduction in Q4 driven by a change in accounting estimates. The Company's stock price fell $0.57 per share on this news, and subsequently, the Company withdrew its full-year 2025 outlook citing prolonged softness in customer capital spending and macroeconomic uncertainty.

Key Takeaways:

  • The class action lawsuit alleges that 3D Systems' top officials made false and misleading statements regarding the Company's business, operations, and compliance policies during the Class Period.
  • The lawsuit centers around the Company's partnership with United Therapeutics Corporation to develop 3D-printed lungs for patients with end-stage lung disease.
  • The updated milestone criteria in the United Partnership negatively impacted the Company's Regenerative Medicine Program revenue.
  • The complaint also claims that 3D Systems had overstated its resilience in the face of weakened customer spending and macroeconomic uncertainty.
  • The lawsuit comes after 3D Systems' financial results for the fourth quarter and full-year 2024 were disappointing.
  • The Company withdrew its full-year 2025 outlook citing prolonged softness in customer capital spending and macroeconomic uncertainty.

Statistics:

  • The lawsuit claims that 3D Systems had overstated its revenue guidance for the first quarter 2025 by $4.17 million and missed consensus estimates by $0.14 per share.
  • The Company reported a net loss of $37 million in the first quarter 2025, more than doubling the $16 million loss reported in the same quarter in 2024.
  • 3D Systems' stock price fell $0.57 per share on March 26, 2025, and subsequently, the Company withdrew its full-year 2025 outlook.

Sources:

  • Pomerantz LLP press release announcing the class action lawsuit against 3D Systems Corporation.
  • 3D Systems Corporation financial results for the fourth quarter and full-year 2024.
  • United Therapeutics Corporation website.
  • Seeking Alpha article by an analyst commenting on 3D Systems' disappointing results.